HEMOPHILIA A AND B
-
WFH mobilizes global community to achieve milestone revisions to WHO EML
While this does not affect Canada directly, it is a major step forward for the international community and acknowledges what Canada is already doing in...
-
CHS research programs: call for applications
The call for applications for the CHS’ research programs for the 2026-2027 grant period is ongoing. The deadline to submit applications for all the programs...
-
CHS educational catalogue
The CHS educational catalogue has been updated. CLICK HERE to take a look at its dynamic online version or to download it as a PDF.
-
Reimbursement of Altuviiio recommended, but…
MONTRÉAL, July 3, 2025 – In June, both Canada’s Drug Agency (CDA) and Quebec’s Institut national d’excellence en santé et en services sociaux (INESSS) released...
-
Hemgenix 4-year results show steady durability
MONTREAL, March 12, 2025 – Results from the HOPE-B trial for the hemophilia B gene therapy, Hemgenix, show steady expression of factor IX (FIX) four...